1. 054 Effect of sarilumab on glycosylated hemoglobin in patients with rheumatoid arthritis and diabetes. (12th April 2019) Authors: Burmester, Gerd R; Hagino, Owen; van Hoogstraten, Hubert; Mangan, Erin; Thangavelu, Karthinathan; Fleischmann, Roy; Wilson, Elaine; Mandrup-Poulsen, Thomas Journal: Rheumatology Issue: Volume 58(2019)Supplement 3 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 074 Summary of indirect comparison to evaluate efficacy of baricitinib with targeted synthetic and biologic disease anti-rheumatic drugs in patients with rheumatoid arthritis. (12th April 2019) Authors: Emery, Paul; Dudler, Jean; Smolen, Josef; Zerbini, Cristiano; Burmester, Gerd; Fautrel, Bruno; van der Laar, Mart; Fleischmann, Roy; Fakhouri, Walid; Leonardis, Francesco De; Zhu, Baojin; Kadziola, Zbigniew; Torre, Inmaculada De La; Perrier, Clementine; Taylor, Peter C Journal: Rheumatology Issue: Volume 58(2019)Supplement 3 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 076 Assessment of pain improvement in rheumatoid arthritis patients treated with baricitinib, who were inadequate responders to methotrexate and tumor necrosis factor inhibitors. (12th April 2019) Authors: Taylor, Peter C; Fleischmann, Roy; Takeuchi, Tsutomu; Pope, Janet; Genovese, Mark C; Zhu, Baojin; Gaich, Carol; Zhang, Xiang; Dickson, Christina; Quebe, Amanda; Leonardis, Francesco De; Cardoso, Anabela; Kouris, Ilias; Durez, Patrick Journal: Rheumatology Issue: Volume 58(2019)Supplement 3 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 081 Long-term safety with sarilumab plus conventional synthetic disease-modifying antirheumatic drugs and sarilumab monotherapy in rheumatoid arthritis: an integrated analysis with 9, 000 patient-years of follow-up. (12th April 2019) Authors: Fleischmann, Roy; Lin, Yong; John, Gregory St; van der Heijde, Désirée; Qiu, Chunfu; Gomez-Reino, Juan Carlos; Maldonado-Cocco, Jose Antonio; Stanislav, Marina; Seriolo, Bruno; Tranter, Lesley; Burmester, Gerd R Journal: Rheumatology Issue: Volume 58(2019)Supplement 3 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. 2019 update of the American College of Rheumatology– recommended rheumatoid arthritis disease activity measures: comment on the article by England et al. Issue 5 (28th April 2020) Authors: Fleischmann, Roy Journal: Arthritis care & research Issue: Volume 72:Issue 5(2020) Page Start: 736 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. 215 Efficacy of sarilumab in combination with csDMARDs in patients with rheumatoid arthritisand inadequate response to TNF inhibitors by baseline levels of diseaseactivity. (25th April 2018) Authors: Fleischmann, Roy; van Hoogstraten, Hubert; Jayawardena, Shyamalie; Mangan, Erin K; Ching, Daniel; Burmester, Gerd R Journal: Rheumatology Issue: Volume 57(2018)Supplement 3 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. 217 Improvementsin remission and low disease activity are achieved with ongoing sarilumabtreatment, in patients with rheumatoid arthritis in two phase III studies. (25th April 2018) Authors: Genovese, Mark C; Mangan, Erin K; Fay, Jon; Kimura, Toshio; van Hoogstraten, Hubert; Fleischmann, Roy Journal: Rheumatology Issue: Volume 57(2018)Supplement 3 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. 221 Development of abatacept- and adalimumab-specific predictive models of response to therapy in rheumatoid arthritis using data from a head-to-head study. (25th April 2018) Authors: Bandyopadhyay, Somnath; Maldonado, Michael A; Ammar, Ron; Schiff, Michael; Weinblatt, Michael; Fleischmann, Roy; Connolly, Sean E Journal: Rheumatology Issue: Volume 57(2018)Supplement 3 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. 4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritis. Issue 1 (14th March 2018) Authors: van der Heijde, Désirée; Deodhar, Atul; FitzGerald, Oliver; Fleischmann, Roy; Gladman, Dafna; Gottlieb, Alice B; Hoepken, Bengt; Bauer, Lars; Irvin-Sellers, Oscar; Khraishi, Majed; Peterson, Luke; Turkiewicz, Anthony; Wollenhaupt, Jürgen; Mease, Philip J Journal: RMD open Issue: Volume 4:Issue 1(2018) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. A Decade of JAK Inhibitors: What Have We Learned and What May Be the Future?. Issue 12 (2nd November 2021) Authors: Liu, Christine; Kieltyka, Jacqueline; Fleischmann, Roy; Gadina, Massimo; O'Shea, John J. Journal: Arthritis & rheumatology Issue: Volume 73:Issue 12(2021) Page Start: 2166 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗